Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Gains from Sales and Divestitures (2016 - 2018)

Alaunos Therapeutics (TCRT) has disclosed Gains from Sales and Divestitures for 8 consecutive years, with $573340.0 as the latest value for Q3 2018.

  • For the quarter ending Q3 2018, Gains from Sales and Divestitures rose 63.81% year-over-year to $573340.0, compared with a TTM value of $573340.0 through Sep 2018, up 63.81%, and an annual FY2017 reading of $778965.0, up 26.11% over the prior year.
  • Gains from Sales and Divestitures was $573340.0 for Q3 2018 at Alaunos Therapeutics, up from $538824.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $778965.0 in Q4 2017 and bottomed at $48433.0 in Q1 2014.
  • Average Gains from Sales and Divestitures over 5 years is $285443.0, with a median of $253835.0 recorded in 2014.
  • The sharpest move saw Gains from Sales and Divestitures crashed 65.11% in 2014, then skyrocketed 393.02% in 2016.
  • Year by year, Gains from Sales and Divestitures stood at $253835.0 in 2014, then crashed by 41.42% to $148694.0 in 2015, then soared by 315.39% to $617666.0 in 2016, then grew by 26.11% to $778965.0 in 2017, then dropped by 26.4% to $573340.0 in 2018.
  • Business Quant data shows Gains from Sales and Divestitures for TCRT at $573340.0 in Q3 2018, $538824.0 in Q2 2018, and $205491.0 in Q1 2018.